TEVA-SOLIFENACIN 10 MG
SOLIFENACIN SUCCINATE : 10 MG · DIN 02397919 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-SOLIFENACIN?
TEVA-SOLIFENACIN 10 MG contains SOLIFENACIN SUCCINATE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02397919, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 30-Jul-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-SOLIFENACIN used for?
Treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urinary urgency and urinary frequency.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02397919 |
|---|---|
| Brand name | TEVA-SOLIFENACIN |
| Generic / active ingredient | SOLIFENACIN SUCCINATE : 10 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04BD08 SOLIFENACIN |
| AHFS class | 86:12.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 30-Jul-2015 |
| Original market date | 2015-07-30 00:00:00 |
How is it administered?
Recommended dose is 5 mg once daily; may be increased to 10 mg if well tolerated. Swallow whole with liquids, with or without food. Max effect seen after 4 weeks.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (standard stability mentioned in TOC but section content missing).
How is it supplied?
Not explicitly detailed in the provided text (mentions 5 mg and 10 mg strengths).
Contraindications
Urinary retention, dialysis dependence, gastroparesis, narrow angle glaucoma, and hypersensitivity to the drug or any ingredient.
Warnings and precautions
Risk of angioedema (potentially life-threatening), anaphylaxis, urinary retention, and heat prostration. May cause blurred vision/somnolence. Caution in patients with QT prolongation risk.
What can be used instead?
Other Canadian products sharing ATC code G04BD08 SOLIFENACIN. 24 of 42 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-SOLIFENACIN SUCCINATE | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02439352 |
| ACH-SOLIFENACIN SUCCINATE | 5 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02439344 |
| AURO-SOLIFENACIN | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02446383 |
| AURO-SOLIFENACIN | 5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02446375 |
| BIO-SOLIFENACIN | 10 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02516527 |
| BIO-SOLIFENACIN | 5 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02516519 |
| JAMP SOLIFENACIN SUCCINATE | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02428938 |
| JAMP SOLIFENACIN SUCCINATE | 5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02428911 |
| PMS-SOLIFENACIN | 10 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02417731 |
| PMS-SOLIFENACIN | 5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02417723 |
Who else supplies SOLIFENACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SOLIFENACIN appears in 235 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.